In early 2026, the FDA opened a voluntary pilot inviting mid-size drug and device manufacturers to benchmark their quality systems against a new maturity model. For companies outside the top-tier pharma bracket, the pilot raises a practical question: is this worth the operational lift right now, or a program to watch from the sidelines for another cycle?
What the pilot actually asks for
The framework scores four areas: management commitment to quality, process capability and controls, deviation and CAPA effectiveness, and supply chain oversight. Unlike an inspection, there’s no citation risk in participating — but the FDA has signaled that maturity ratings may eventually factor into inspection frequency and import screening priority, which changes the calculus for smaller manufacturers with limited quality headcount.
Our take
Companies with fewer than 500 employees and a single US manufacturing site should treat this as a low-risk dry run rather than a compliance obligation. Use the self-assessment worksheet internally first, without submitting scores, to see where your CAPA closure times and deviation trending would land against the published benchmarks. If your numbers are already solid, formal participation costs little and builds a documented track record ahead of any future tie to inspection scheduling. If they’re not, that’s useful information to have before FDA does.